[
  {
    "ts": null,
    "headline": "Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants",
    "summary": "HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced two new hires to its team for CNSide Diagnostics, LLC, its wholly-owned subsidiary. “We are strategically building the team to bolster our capabilities as we scale up our laboratory operations to address the largely unt",
    "url": "https://finnhub.io/api/news?id=637abf8cccdfbf61131b42b7de6c4b4ee07c0f0dc2a110bd627ec61f7b9b9dc9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765283400,
      "headline": "Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants",
      "id": 137740484,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HUM",
      "source": "Yahoo",
      "summary": "HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced two new hires to its team for CNSide Diagnostics, LLC, its wholly-owned subsidiary. “We are strategically building the team to bolster our capabilities as we scale up our laboratory operations to address the largely unt",
      "url": "https://finnhub.io/api/news?id=637abf8cccdfbf61131b42b7de6c4b4ee07c0f0dc2a110bd627ec61f7b9b9dc9"
    }
  }
]